Table 2.

Ongoing Clinical Trials with Enfortumab Vedotin in Advanced or Metastatic Bladder Cancer Patients

Trial	NCT, No.	Phase	Comparison	Line of Treatment	Endpoints
EV-103	03288545	1b	EV + P EV + CTX EV + P + CTX	First-line or later-line	Primary: TEAEs Secondary: OS, PFS, ORR, DCR, DOR
EV-301	03474107	3	EV CTX	Later-line	Primary: OS Secondary: PFS, ORR, DOR, TEAEs
EV-302	04223856	3	EV + P CTX EV + P + CTX	First-line	Primary: PFS/OS Secondary: ORR, DOR, DCR, TEAEs

Abbreviations: CTX, chemotherapy; DCR, disease control rate; DOR, duration of response; EV, enfortumab vedotin; ORR, overall response rate; OS, overall survival; P, pembrolizumab; PFS, progression-free survival; TEAE, treatment emergent adverse event.